Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

Company Overview - Regenxbio is a clinical-stage biopharmaceutical company that specializes in gene therapies, founded in 2008 [1] - The company's core technology involves the delivery of rescue genes using AAV (adeno-associated virus) payloads, which is increasingly being utilized in approved drugs [1] Industry Insights - The healthcare sector is complex, and financial professionals and investors require scientific and clinical expertise to navigate it effectively [1] - There is a growing emphasis on bridging the gap between advanced scientific research and financial strategy to uncover hidden value and assess risks accurately in life sciences [1]